HIV prevalence is increasing worldwide because people on antiretroviral therapy are living
longer, although new infections decreased from 3· 3 million in 2002, to 2· 3 million in 2012 …

The sequence of microbial genomes made all potential antigens of each pathogen available
for vaccine development. This increased by orders of magnitude potential vaccine targets in …

A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV
infects millions of people worldwide and is a leading cause of liver cirrhosis and …

Despite the development of highly effective prophylactic vaccines against human
papillomavirus (HPV) serotypes 16 and 18, prevention of cervical dysplasia and cancer in …

Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the
human population is widespread, thus hampering its clinical use. Various components of the …

Despite anti-retroviral therapy (ART), human immunodeficiency virus-1 (HIV)-related
pulmonary disease continues to be a major cause of morbidity and mortality for people living …

Background Vaccines have provided some of the greatest successes in the history of
medicine, including the eradication of smallpox, the near eradication of polio, and the …

Replication-defective adenovirus vectors based on human serotype 5 (Ad5) induce
protective immune responses against diverse pathogens and cancer in animal models, as …

This review discusses peptide epitopes used as antigens in the development of vaccines in
clinical trials as well as future vaccine candidates. It covers peptides used in potential …

We have entered a new era in HIV prevention whereby priorities have expanded from
biomedical discovery to include implementation, effectiveness, and the effect of combination …